Folate vs Folic Acid in Pregnancy: What MTHFR Means for Future Kids

← Back to articles

Few topics in prenatal nutrition generate more confusion than the folate vs folic acid vs methylfolate distinction. The basic facts are unambiguous: periconceptional folate supplementation reduces neural tube defects (NTDs) by 50–70%. The newer wrinkle is the MTHFR genotype question, where social-media advice has run far ahead of the genetics evidence.

The Forms

Folic acid is the synthetic, oxidized form added to fortified flour and most prenatals. It is converted in the liver to dihydrofolate, then tetrahydrofolate, then 5-methyltetrahydrofolate (5-MTHF), the active circulating form. Folate is the umbrella term for the family of compounds and includes naturally occurring food folates (mostly in leafy greens, legumes, citrus). Methylfolate (5-MTHF, sold as Metafolin or Quatrefolic) is the supplemental form that bypasses the conversion steps.

The MTHFR C677T Variant

The most-studied MTHFR variant, C677T, reduces the activity of the methylenetetrahydrofolate reductase enzyme. Heterozygotes (CT) have ~65% activity, homozygotes (TT) ~30%. About 10–15% of people of European ancestry and up to 25% of people of Hispanic ancestry are TT. The variant is associated with mildly elevated homocysteine and a small increase in NTD risk in offspring — but the practical implication is smaller than the marketing suggests.

What the Trials Actually Show

The 1991 MRC Vitamin Study and the Czech double-blind 1992 trial established that 4 mg/day folic acid prevents recurrent NTDs (relative risk 0.28). Subsequent studies confirmed that 400–800 mcg/day folic acid prevents first-occurrence NTDs in the general population. These trials used folic acid, not 5-MTHF, and were conducted across populations with the full range of MTHFR genotypes. The protective effect held.

Head-to-head trials of folic acid vs 5-MTHF have shown comparable increases in red blood cell folate. The Lamers 2006 trial in the American Journal of Clinical Nutrition found that 5-MTHF raised RBC folate slightly more efficiently per dose unit, particularly in TT homozygotes. There are no NTD-prevention trials showing 5-MTHF outperforms folic acid because the necessary trial size makes such studies impractical.

Practical Recommendation

For most women planning pregnancy, 400–800 mcg/day of either folic acid or 5-MTHF is appropriate, beginning at least one month before conception and continuing through the first trimester. Women with a personal or family history of NTDs should receive 4 mg/day under medical supervision. Women known to be MTHFR TT homozygous can reasonably choose 5-MTHF, but the absolute clinical benefit over folic acid is small and unproven for NTD prevention.

The Genetic-Testing Industry Caveat

Direct-to-consumer MTHFR testing has driven anxiety far beyond what the evidence supports. The American College of Medical Genetics (ACMG) explicitly recommends against routine MTHFR genotyping in the workup of recurrent pregnancy loss, thrombophilia, or general preconception care. The variant is too common and the clinical implications too modest to justify population-wide testing. Women whose providers have tested them and reported a TT result should still take folate — in either form — periconceptionally.

Don't Forget the Mandatory Fortification Floor

Since 1998, the U.S. has required folic acid fortification of enriched grain products. NTD rates fell 23–28% within years of the mandate. Women trying to avoid synthetic folic acid by eating only unfortified flour need to be much more deliberate about leafy greens and supplementation — the cushion that fortification provides is meaningful.